Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease

Cancer Journal

Volumn 13, Issue 6, 2007, Pages 384-391

  Pardanani, Animesh ^a   Verstovsek, Srdan ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Eosinophilia; Mastocytosis; Myeloproliferative disorders

Indexed keywords

ALEMTUZUMAB; CLADRIBINE; CORTICOSTEROID; HYDROXYUREA; IMATINIB; MEPOLIZUMAB; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PREDNISONE; RECOMBINANT ALPHA INTERFERON;

ANAPHYLAXIS; BONE MARROW EXAMINATION; BONE MARROW SUPPRESSION; BONE PAIN; CHRONIC LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; CYTOPENIA; DEPRESSION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; FEVER; FLU LIKE SYNDROME; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOPROLIFERATIVE DISEASE; MAST CELL; MAST CELL DISEASE; MAST CELL DISSEASE; MASTOCYTOSIS; MULTIPLE CYCLE TREATMENT; MUTATION; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; ARTICLE; CHRONIC DISEASE; FEMALE; GENETICS; MALE;

CHRONIC DISEASE; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; MASTOCYTOSIS;

EID: 39749189511     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31815a9618     Document Type: Review

References (114)

1. Brigden M, Graydon C. Eosinophilia detected by automated blood cell counting in ambulatory North American outpatients: incidence and clinical significance. Arch Pathol Lab Med. 1997;121:963-967.
2. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006;133:468-492.
3. Strath M, Sanderson CJ. Detection of eosinophil differentiation factor and its relationship to eosinophilia in Mesocestoides corti-infected mice. Exp Hematol. 1986;14:16-20.
4. Yamaguchi Y, Matsui T, Kasahara T, et al. In vivo changes of hemopoietic progenitors and the expression of the interleukin 5 gene in eosinophilic mice infected with Toxocara canis. Exp Hematol. 1990; 18:1152-1157.
5. Hamid Q, Azzawi M, Ying S, et al. Expression of mRNA for inter-leukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest. 1991;87:1541-1546.
6. Brunning RD, McKenna RW, Rosai J, et al. Systemic mastocytosis. Extracutaneous manifestations. Am J Surg Pathol. 1983;7:425-438.
7. Horny HP, Parwaresch MR, Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol. 1985;16:808-814.
8. Stevens EC, Rosenthal NS. Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease. Am J Clin Pathol. 2001;116:177-182.
9. Escribano L, Orfao A, Diaz-Agustin B, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998;91: 2731-2736.
10. Schernthaner GH, Jordan JH, Ghannadan M, et al. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood. 2001;98:3784-3792.
11. Pardanani A, Kimlinger T, Reeder T, et al. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res. 2004;28:777-783.
12. Bain B, Pierre R, Imbert M, et al. Chronic eosinophilic leukemia and the hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer (IARC) Press; 2001:29-31.
13. Simon HU, Plotz SG, Dummer R, et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341:1112-1120.
14. Butterfield JH. Diverse clinical outcomes of eosinophilic patients with T-cell receptor gene rearrangements: the emerging diagnostic importance of molecular genetics testing. Am J Hematol. 2001;68:81-86.
15. Chang HW, Leong KH, Koh DR, et al. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood. 1999;93:1651-1657.
16. Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol. 2004;77:82-85.
17. Fauci AS, Harley JB, Roberts WC, et al. NIH conference. The idiopathic hypereosinophilic syndrome: clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med. 1982;97:78-92.
18. Harley JB, Fauci AS, Gralnick HR. Noncardiovascular findings associated with heart disease in the idiopathic hypereosinophilic syndrome. Am J Cardiol. 1983;52:321-324.
19. Moore PM, Harley JB, Fauci AS. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med. 1985;102: 109-114.
20. Liapis H, Ho AK, Brown D, et al. Thrombotic microangiopathy associated with the hypereosinophilic syndrome. Kidney Int. 2005;67: 1806-1811.
21. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759-2779.
22. Ommen SR, Seward JB, Tajik AJ. Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol. 2000;86:110-113.
23. Lefebvre C, Bletry O, Degoulet P, et al. Prognostic factors of hypereosinophilic syndrome: study of 40 cases. Ann Med Interne (Paris). 1989;140:253-257.
24. Leiferman KM, O'Duffy JD, Perry HO, et al. Recurrent incapacitating mucosal ulcerations: a prodrome of the hypereosinophilic syndrome. JAMA. 1982;247:1018-1020.
25. Sato Y, Taniguchi R, Yamada T, et al. Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder. Intern Med. 2000;39:350.
26. Pitini V, Arrigo C, Azzarello D, et al. Serum concentration of cardiac troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood. 102:3456-3457, 2003; author reply 3457.
27. Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med. 1978;89:167-172.
28. Butterfield JH, Gleich GJ. Interferon-α treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med. 1994;121: 648-653.
29. Baratta L, Afeltra A, Delfino M, et al. Favorable response to high-dose interferon-α in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy - case report and literature review. Angiology. 2002; 53:465-470.
30. Yoon TY, Ahn GB, Chang SH. Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review. J Dermatol. 2000;27:110-115.
31. Ceretelli S, Capochiani E, Petrini M. Interferon-α in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ann Hematol. 1998;77:161-164.
32. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104:3038-3045.
33. Sefcick A, Sowter D, DasGupta E, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol. 2004;124:558-559.
34. Pitini V, Teti D, Arrigo C, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol. 2004;127:477.
35. Koury MJ, Newman JH, Murray JJ. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. Am J Med. 2003;115:587-589.
36. Plotz SG, Simon HU, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med. 2003;349:2334-2339.
37. Klion AD, Law MA, Noel P, et al. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood. 2004;103:2939-2941.
38. Kim YJ, Prussin C, Martin B, et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol. 2004;114:1449-1455.
39. Score J, Curtis C, Waghorn K, et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia. 2006;20:827-832.
40. Baxter EJ, Hochhaus A, Bolufer P, et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet. 2002;11:1391-1397.
41. Walz C, Curtis C, Schnittger S, et al. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer. 2006.
42. Bacher U, Reiter A, Haferlach T, et al. A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia. Haematologica. 2006;91: 817-820.
43. Pardanani A, Ketterling RP, Li CY, et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res. 2006;30:965-970.
44. Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Blood. 2007;109:4635-4640.
45. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102:3093-3096.
46. Golub TR, Barker GF, Lovett M, et al. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307-316.
47. Abe A, Emi N, Tanimoto M, et al. Fusion of the platelet-derived growth factor receptor β to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood. 1997;90:4271-4277.
48. Levine RL, Wadleigh M, Sternberg DW, et al. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia. 2005;19:27-30.
49. Vizmanos JL, Novo FJ, Roman JP, et al. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res. 2004;64:2673-2676.
50. Morerio C, Acquila M, Rosanda C, et al. HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17) (q33;p11. 2). Cancer Res. 2004;64:2649-2651.
51. Wilkinson K, Velloso ER, Lopes LF, et al. Cloning of the t(1;5) (q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood. 2003;102: 4187-4190.
52. Magnusson MK, Meade KE, Brown KE, et al. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood. 2001;98:2518-2525.
53. Ross TS, Bernard OA, Berger R, et al. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor β receptor (PDGFβR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood. 1998;91:4419-4426.
54. Schwaller J, Anastasiadou E, Cain D, et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor β gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood. 2001;97:3910-3918.
55. Grand FH, Burgstaller S, Kuhr T, et al. p53-binding protein 1 is fused to the platelet-derived growth factor receptor β in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res. 2004;64:7216-7219.
56. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N Engl J Med. 2002;347:481-487.
57. Walz C, Metzgeroth G, Haferlach C, et al. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor β gene. Haematologica. 2007;92:163-169.
58. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002;107:101-107.
59. Still IH, Chernova O, Hurd D, et al. Molecular characterization of the t(8;13)(p11;q12) translocation associated with an atypical myeloproliferative disorder: evidence for three discrete loci involved in myeloid leukemias on 8p11. Blood. 1997;90:3136-3141.
60. Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet. 1998;18:84-87.
61. Smedley D, Hamoudi R, Clark J, et al. The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. Hum Mol Genet. 1998;7:637-642.
62. Popovici C, Adelaide J, Ollendorff V, et al. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proc Natl Acad Sci USA. 1998;95:5712-5717.
63. Reiter A, Sohal J, Kulkarni S, et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood. 1998;92:1735-1742.
64. Vaklavas C, Tefferi A, Butterfield J, et al. 'Idiopathic' eosinophilia with an occult T-cell clone: prevalence and clinical course. Leuk Res. 2007;31:691-694.
65. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001; 25:603-625.
66. Valent P. Diagnostic evaluation and classification of mastocytosis. Immunol Allergy Clin North Am. 2006;26:515-534.
67. Castells M, Austen KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol. 2002;127:147-152.
68. Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol. 1991;96:5S-13S; discussion 13S-14S.
69. Horny HP, Sotlar K, Sperr WR, et al. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol. 2004;57:604-608.
70. Sagher F, Even-Paz Z. Mastocytosis and the Mast Cell. Chicago: Year Book Medical Publishers; 1967.
71. Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: a review. Histopathology. 1979;3:349-365.
72. Horny HP, Ruck M, Wehrmann M, Kaiserling E. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br J Haematol. 1990;76:186-193.
73. Travis WD, Li CY, Yam LT, et al. Significance of systemic mast cell disease with associated hematologic disorders. Cancer. 1988;62:965-972.
74. Sperr WR, Horny HP, Lechner K, et al. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma. 2000;37:473-486.
75. Valent P, Sperr WR, Schwartz LB, et al. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol. 114:3-11, 2004; quiz 12.
76. Horny HP, Sillaber C, Menke D, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol. 1998;22:1132-1140.
77. Horny HP, Valent P. Histopathological and immunohistochemical aspects of mastocytosis. Int Arch Allergy Immunol. 2002;127:115-117.
78. Jordan JH, Walchshofer S, Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol. 2001;32:545-552.
79. Sotlar K, Horny HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol. 2004;28:1319-1325.
80. Escribano L, Garcia Montero AC, Nunez R, et al. Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease. Immunol Allergy Clin North Am. 2006;26:535-547.
81. Schwartz LB, Metcalfe DD, Miller JS, et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med. 1987;316:1622-1626.
82. Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn. 2006;8:412-419.
83. Sotlar K, Fridrich C, Mall A, et al. Detection of c-kit point mutation Asp-816 → Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk Res. 2002;26:979-984.
84. Pardanani A, Reeder T, Li CY, et al. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res. 2003;27:883-885.
85. Yavuz AS, Lipsky PE, Yavuz S, et al. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from singlecell analysis of mutations in the c-kit gene. Blood. 2002;100:661-665.
86. Sotlar K, Escribano L, Landt O, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 2003;162:737-746.
87. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow haematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108:2366-2372.
88. Lawley W, Hird H, Mallinder P, et al. Detection of an activating c-kit mutation by real-time PCR in patients with anaphylaxis. Mutat Res. 2005;572:1-13.
89. Greenblatt EP, Chen L. Urticaria pigmentosa: an anesthetic challenge. J Clin Anesth. 1990;2:108-115.
90. Lerno G, Slaats G, Coenen E, et al. Anaesthetic management of systemic mastocytosis. Br J Anaesth. 1990;65:254-257.
91. Scott HW Jr, Parris WC, Sandidge PC, et al. Hazards in operative management of patients with systemic mastocytosis. Ann Surg. 1983; 197:507-514.
92. Rosenbaum KJ, Strobel GE. Anesthetic considerations in mastocytosis. Anesthesiology. 1973;38:398-401.
93. Turk J, Oates JA, Roberts LJ 2nd. Intervention with epinephrine in hypotension associated with mastocytosis. J Allergy Clin Immunol. 1983;71:189-192.
94. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-a: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002;119:1090-1097.
95. Kluin-Nelemans HC, Jansen JH, Breukelman H, et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med. 1992;326:619-623.
96. Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol. 1998;138:489-495.
97. Kolde G, Sunderkotter C, Luger TA. Treatment of urticaria pigmentosa using interferon α. Br J Dermatol. 1995;133:91-94.
98. Lehmann T, Beyeler C, Lammle B, et al. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon α-2B. Br J Rheumatol. 1996;35:898-900.
99. Weide R, Ehlenz K, Lorenz W, et al. Successful treatment of osteoporosis in systemic mastocytosis with interferon α-2b. Ann Hematol 1996;72:41-43.
100. Butterfield JH, Tefferi A, Kozuh GF. Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case. Leuk Res. 2005;29:131-134.
101. Takasaki Y, Tsukasaki K, Jubashi T, et al. Systemic mastocytosis with extensive polypoid lesions in the intestines; successful treatment with interferon-α. Intern Med. 1998;37:484-488.
102. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon α-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res. 2004;28:249-257.
103. Petit A, Pulik M, Gaulier A, et al. Systemic mastocytosis associated with chronic myelomonocytic leukemia: clinical features and response to interferon alfa therapy. J Am Acad Dermatol. 1995;32: 850-853.
104. Lehmann T, Lammle B. IFNa treatment in systemic mastocytosis. Ann Hematol. 1999;78:483-484.
105. Lippert U, Henz BM. Long-term effect of interferon α treatment in mastocytosis.[comment]. Br J Dermatol. 1996;134:1164-1165.
106. Pardini S, Bosincu L, Bonfigli S, et al. Anaphylactic-like syndrome in systemic mastocytosis treated with α-2-interferon. Acta Haematol. 1991;85:220.
107. Tefferi A, Li CY, Butterfield JH, et al. Treatment of systemic mast-cell disease with cladribine. N Engl J Med. 2001;344:307-309.
108. Pardanani A, Hoffbrand AV, Butterfield JH, et al. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res. 2004; 28:127-131.
109. Escribano L, Perez de Oteyza J, Nunez R, et al. Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis: report of a case of mastocytosis associated with a lymphoplasmacytic lymphoma. Leuk Res. 2002;26:1043-1046.
110. Schleyer V, Meyer S, Landthaler M, et al. "Smoldering systemic mastocytosis": successful therapy with cladribine. Hautarzt. 2004;55: 658-662.
111. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102:4270-4276.
112. Lortholary O, Vargaftig J, Feger F, et al. Efficacy and safety of cladribine in adult systemic mastocytosis. Blood. 2004;104:190a.
113. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet. 2003;362:535-536.
114. Musto P, Falcone A, Sanpaolo G, et al. Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis. Leuk Res. 2004;28:421- 422.